Standout Papers

Phase II Trial of Sorafenib in Advanced Thyroid Cancer 2008 2026 2014 2020 526
  1. Phase II Trial of Sorafenib in Advanced Thyroid Cancer (2008)
    Vandana G. Abramson, Andrea B. Troxel et al. Journal of Clinical Oncology

Immediate Impact

8 from Science/Nature 80 standout
Sub-graph 1 of 20

Citing Papers

Cutaneous melanoma
2023 Standout
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
2023 Standout
2 intermediate papers

Works of Maryann Redlinger being referenced

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
2009
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
2008

Author Peers

Author Last Decade Papers Cites
Maryann Redlinger 519 456 191 445 25 1.1k
Shanhong Tang 504 512 71 440 30 1.1k
Yifah Yaron 608 328 376 610 17 1.3k
Michael E. Menefee 596 474 204 544 44 1.3k
Hitoyasu Futami 417 325 113 212 41 856
Francesca Del Monte 442 301 159 127 26 973
Cheng–Lung Hsu 270 295 286 159 30 1.1k
Bruno Torchio 276 193 203 363 37 955
Anna Fioravanti 398 325 190 213 38 888
Benedetta Donati 230 671 127 284 42 1.3k
Roderick M. Quiros 441 428 167 518 34 1.3k

All Works

Loading papers...

Rankless by CCL
2026